Biocompatible dialysis fluids for peritoneal dialysis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Cho, Yeoungjee ^a   Johnson, David W ^a   Craig, Jonathan C ^b,c   Strippoli, Giovanni F M ^b,c,d,e   Badve, Sunil V ^a   Wiggins, Kathryn J ^f  

^a Princess AlexandraHospital ^*  (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF BARI   (Italy)

^e Medical Scientific Office   (Sweden)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; BIOCOMPATIBLE DIALYSIS FLUID; CREATININE; GLUCOSE POLYMER; GUANOSINE DIPHOSPHATE; ICODEXTRIN; LACTIC ACID; PERITONEAL DIALYSIS FLUID; UNCLASSIFIED DRUG;

AUTOMATED PERITONEAL DIALYSIS; BLOOD PRESSURE; BLOOD VOLUME; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIALYSATE; DRUG SAFETY; FLUID BALANCE; HEMODIALYSIS; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PH; QUALITY OF LIFE; RASH; REVIEW; SURVIVAL; TREATMENT OUTCOME; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; URINE VOLUME;

EID: 70249140543     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007554     Document Type: Review

References (20)

1. Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology 2001;12(10):2158-2162 [MEDLINE: 11562415]
2. Cueto-Manzano AM, Rojas-Campos E. Status of renal replacement therapy and peritoneal dialysis in Mexico. Peritoneal Dialysis International 2007;27(2):142-148 [MEDLINE: 17299147] (Pubitemid 46795865)
3. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560 [MEDLINE: 12958120]
4. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008. Available from www.cochrane-handbook.org.
5. Johnson D, McDonald S, Excell L, Livingston B, Shtangey V. Peritoneal dialysis. In: McDonald S, Excell L editor(s). ANZDATA registry report 2005. Adelaide: ANZDATA, 2006:84-100.
6. Jorres A, Topley N, Gahl GM. Biocompatibility of peritoneal dialysis fluids. International Journal of Artificial Organs 1992;15(2):79-83. [MEDLINE: 1555880]
7. Lamb EJ, Cattell WR, Dawnay AB. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney International 1995;47(6):1768-1774 [MEDLINE: 7643548]
8. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org.
9. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2007).
10. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Peritoneal Dialysis International 1999;19(6):517-525 [MEDLINE: 10641771] (Pubitemid 30015564)
11. Mortier S, Lameire NH, De Vriese AS. The effects of peritoneal dialysis solutions on peritoneal host defense. Peritoneal Dialysis International 2004;24(2):123-138 [MEDLINE: 15119633] (Pubitemid 38515076)
12. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al.Immunohistochemical detection of advanced glycosylation end-products in the peritoneumand its possible pathophysiological role in CAPD. Kidney International 1997;51(1):182-186 [MEDLINE: 8995732] (Pubitemid 27064536)
13. Nilsson-Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Peritoneal Dialysis International 1993;13(3):208-213 [MEDLINE: 8369351] (Pubitemid 23235969)
14. Palmer B. Dialysate composition in hemodialysis and peritoneal dialysis. In: Henrich WL editor(s). Principles and practice of dialysis. 3rd Edition. Lippincott Williams and Wilkins, 2004.
15. Pollock C. Pathogenesis of peritoneal sclerosis. International Journal of Artificial Organs 2005;28(2):90-96 [MEDLINE: 15770596]
16. Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC. Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, Issue 1. Art. No.: RENAL (accessed March 2008).
17. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrology Dialysis Transplantation 1998;13(1):154-159 [MEDLINE: 9481732]
18. Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Peritoneal Dialysis International 1997;17(1):42-47 [MEDLINE: 9068021] (Pubitemid 27475046)
19. Wieslander A, Forsback G, Svensson E, Linden T. Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluid. Advances in Peritoneal Dialysis 1996;12:57-60. [MEDLINE: 8865874]
20. Williams JD, Craig KJ, Topley N, Williams GT. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney International - Supplement 2003, (84):S158-61. [MEDLINE: 12694335] (Pubitemid 36513400)